TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31211964

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 364

Group type: COMPARATOR
Intervention: Sacral neuromodulation
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (subgroup with Vaizey score ≥12)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Sacral neuromodulation (subgroup with Vaizey score ≥12)
Number of subjects: 364
Study: 29792728

Group type: EXPERIMENTAL
Intervention: Triple-bolus DECT
Number of subjects: 118

Group type: COMPARATOR
Intervention: Triple-phase MDCT
Number of subjects: 118
Study: 26727506

Group type: EXPERIMENTAL
Intervention: High-dose trans-resveratrol (450 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-dose trans-resveratrol (150 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24183737

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of antibiotic (1g of amoxicillin); no postoperative antibiotics.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative dose of antibiotic (1g of amoxicillin) followed by a 3-day postoperative course.
Number of subjects: 80
Study: 22160483

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study: 21198221

Group type: EXPERIMENTAL
Intervention: Participatively set goals
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Assigned goals
Number of subjects: 126

Group type: COMPARATOR
Intervention: No goal condition
Number of subjects: 126
Study: 17474873

Group type: EXPERIMENTAL
Intervention: Traditional Mediterranean diet for 6 months
Number of subjects: 115

Group type: COMPARATOR
Intervention: Regular diet (Control)
Number of subjects: 115
Study: 12971031

Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with 12 ounces of water
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal with milk
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal without milk
Number of subjects: 14
Study: 11039508

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFX) 2,000 mg/m2 IV infusion days 1 to 3; 2-mercaptoethanesulfonic acid sodium salt (mesna) 400 mg/m2 IV bolus H 0 and 4, 800 mg/m2 by mouth H 8, days 1 to 3; Vinorelbine (VNB) 25 mg/m2 IV infusion days 1 and 8; Cisplatin (CDDP) 75 mg/m2 IV day 3, repeated every 28 days for a total of three courses
Number of subjects: 40
Study: 9322500

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.14 mg.kg‐1.day‐1), oral glutamine (0.63 g.kg‐1.day‐1), and high carbohydrate-low fat diet for 21 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1436129

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3467504

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dye laser iridotomy
Number of subjects: 100
Study: 31230661

Group type: EXPERIMENTAL
Intervention: Colposcopic surveillance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pap testing
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 125
Study: 30419961

Group type: EXPERIMENTAL
Intervention: Combination of conventional medicine and Traditional Chinese Medicine (TCM), administered twice daily for 28 days.
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional medicine alone (control group).
Number of subjects: 198
Study: 26880794

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 67
Study: 25292072

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 80
Study: 23019943

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy combined with Kanglaite Injection (KI) at 100 mL/d for 21 days, two cycles with one week interval.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gemcitabine and concurrent 3D‐CRT (Control group).
Number of subjects: 50
Study: 20110554

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 961

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 961
Study: 17651563

Group type: EXPERIMENTAL
Intervention: Inanimate box trainer (LTS 2000) for 10 sessions (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inanimate box trainer (LTS 2000) and virtual reality trainer (MIST-VR) for 10 sessions (Group B)
Number of subjects: 32
Study: 16401690

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14693180

Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LPS (ex vivo incubation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LPS (2-4 h after infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LPS (24 h after challenge)
Number of subjects: 30
Study: 11339569

Group type: EXPERIMENTAL
Intervention: Telediagnostic procedures using digital images of cytological slides
Number of subjects: 54
Study: 9240631

Group type: EXPERIMENTAL
Intervention: Register-based definition of CHD including all CHD deaths and hospitalizations with the ICD-8 code 410
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HHS results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wider definition of CHD including ICD-8 and ICD-9 codes 410-414
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definite AMI as a single definition of CHD
Number of subjects: 0
Study: 8238173

Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg/day for three menstrual cycles (n = 19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Reduced-dose danazol regimen (200 mg/day for one cycle, 100 mg/day for one cycle, and 50 mg/day for one cycle) (n = 19)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Norethindrone, 5 mg three times daily on days 19 through 26 of the cycle for three consecutive cycles (n = 19)
Number of subjects: 57
Study: 3086204

Group type: EXPERIMENTAL
Intervention: Vasopressin plus nitroglycerin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 57
Study: 31342246

Group type: EXPERIMENTAL
Intervention: On-clamp RAPN
Number of subjects: 302

Group type: COMPARATOR
Intervention: Off-clamp RAPN
Number of subjects: 302
Study: 28872404

Group type: EXPERIMENTAL
Intervention: Operative treatment (lateral retinacular release and medial retinacular repair)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nonoperative treatment (patellar bracing and quadriceps strengthening)
Number of subjects: 3
Study: 26701796

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) containing 843 mg (‐)‐epigallocatechin‐3‐gallate
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE)
Number of subjects: 121
Study: 24491078

Group type: EXPERIMENTAL
Intervention: Immediate condition (10 weeks of web‐based self‐help via StopPulling.com)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Step 2 (8 sessions of in‐person habit reversal training [HRT])
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Entire stepped care program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist (WL) condition
Number of subjects: 60
Study: 22790524

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program focused on exercise and diet behavior
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 107
Study: 20430262

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (up to 54 mug) 4 times daily
Number of subjects: 235

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 235
Study: 18955906

Group type: EXPERIMENTAL
Intervention: Gestalt grouping cues (proximity or similarity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurological patients with damage to the inferior parietal regions
Number of subjects: 0
Study: 16201941

Group type: EXPERIMENTAL
Intervention: Coated polyglactin 910 suture with triclosan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coated polyglactin 910 suture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both sutures
Number of subjects: 0
Study: 12417963

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10536564

Group type: EXPERIMENTAL
Intervention: ParaGraph neuromuscular monitor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relaxometer 2 mechanomyograph
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both monitors
Number of subjects: 20
Study: 8652332

Group type: EXPERIMENTAL
Intervention: MgSO4 60 mg kg‐1 at recovery from vecuronium block to a TOF ratio of 0.7
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MgSO4 60 mg kg‐1 1 h after recovery to a TOF ratio of 0.7
Number of subjects: 20
Study: 1853696

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide-oxygen (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Air-oxygen (Group II)
Number of subjects: 50
Study: 6354282

Group type: EXPERIMENTAL
Intervention: Prednisolone (200‐300 mg over 48‐72 h)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 397
Study: 30515964

Group type: EXPERIMENTAL
Intervention: Forward-backward method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dual-panel method
Number of subjects: 60
Study: 28841725

Group type: EXPERIMENTAL
Intervention: Tinnitus loudness rating
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tinnitus loudness matching test
Number of subjects: 91
Study: 25956017

Group type: EXPERIMENTAL
Intervention: Educational intervention (2 interactive classroom sessions about sugar)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 268
Study: 23603409

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogenic treatment
Number of subjects: 0
Study: 21502892

Group type: EXPERIMENTAL
Intervention: Exercise training with weight loss
Number of subjects: 22

Group type: COMPARATOR
Intervention: Exercise training without weight loss
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nonexercising)
Number of subjects: 22
Study: 18180279

Group type: EXPERIMENTAL
Intervention: 1 ml triamcinolonacetonide (TCA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 50
Study: 16480828

Group type: EXPERIMENTAL
Intervention: Contralateral epidural stimulation electrodes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Double-blind testing
Number of subjects: 17
Study: 15483019

Group type: EXPERIMENTAL
Intervention: Cisplatin monotherapy (3 postoperative courses)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Remaining group (not specified treatment)
Number of subjects: 35
Study: 11154750

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 271
Study: 9356089

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 214

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 214
Study: 8502373

Group type: EXPERIMENTAL
Intervention: Frequent non-target tones (P=0.70)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Target-evoked N2 and P3b components
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Novel stimuli
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P3a component
Number of subjects: 16
Study: 2949481

Group type: EXPERIMENTAL
Intervention: CA 2 mg + EE 50 micrograms (Diane)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CA 2 mg + EE 35 micrograms (Diane mite)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Levonorgestrel 150 micrograms + EE 30 micrograms (Neovletta)
Number of subjects: 133
Study: 30852167

Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Higher star-rated NHs
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Champions' participation in check-in calls
Number of subjects: 119
Study: 28783413

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 µg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study: 28821523

Group type: EXPERIMENTAL
Intervention: Pragmatic school-based universal resilience intervention (2012-2014)
Number of subjects: 2105
Study: 26302900

Group type: EXPERIMENTAL
Intervention: Bouldering intervention (once a week for three hours over eight weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waitlist control group (treatment as usual for eight weeks)
Number of subjects: 47
Study: 23473357

Group type: EXPERIMENTAL
Intervention: HF‐rTMS
Number of subjects: 392
Study: 21209131

Group type: EXPERIMENTAL
Intervention: Two 90 min team-skills training sessions focused on findings from a standardised safety-culture survey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (pre-intervention period)
Number of subjects: 0
Study: 18081357

Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg IV and 20 mg orally)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Furosemide (40 mg IV and 80 mg orally)
Number of subjects: 21
Study: 16958947

Group type: EXPERIMENTAL
Intervention: milameline
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 12768948

Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 25

Group type: COMPARATOR
Intervention: human insulin 30/70
Number of subjects: 25
Study: 11575978

Group type: EXPERIMENTAL
Intervention: Ximelagatran 8 mg twice daily
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ximelagatran 12 mg twice daily
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ximelagatran 18 mg twice daily
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ximelagatran 24 mg twice daily
Number of subjects: 600

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg subcutaneously twice daily
Number of subjects: 600
Study: 9713666

Group type: EXPERIMENTAL
Intervention: Interactive method using simulated patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Didactic method
Number of subjects: 12
Study: 8201222

Group type: EXPERIMENTAL
Intervention: Interferon therapy (alone or in combination with corticosteroid withdrawal)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interferon therapy (alone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 50
Study: 2740834

Group type: EXPERIMENTAL
Intervention: Combination of CH and Triton X‐100
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorhexidine alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 10
Study: 31603351

Group type: EXPERIMENTAL
Intervention: Telehomecare (THCa) system for transmission and online analysis of capillary glucose data
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care in the clinic
Number of subjects: 161
Study: 28754483

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg in two 150 mg tablets, twice daily)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 295
Study: 25816723

Group type: EXPERIMENTAL
Intervention: Forward-viewing echoendoscope
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oblique-viewing echoendoscope
Number of subjects: 41
Study: 23707402

Group type: EXPERIMENTAL
Intervention: SMS program (n = 23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 52
Study: 21849726

Group type: EXPERIMENTAL
Intervention: Elite cyclists
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (sedentary individuals)
Number of subjects: 128
Study: 19641893

Group type: EXPERIMENTAL
Intervention: Prehospital treatment and emergency management of pediatric trauma patients
Number of subjects: 624

Group type: COMPARATOR
Intervention: Prehospital treatment and emergency management of adult trauma patients
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Pediatric trauma patients
Number of subjects: 624

Group type: COMPARATOR
Intervention: Adult trauma patients
Number of subjects: 624
Study: 17178217

Group type: EXPERIMENTAL
Intervention: HFA-fluticasone propionate 500 microg BD/salmeterol 100 microg BD/HFA-tiotropium bromide 18 microg od
Number of subjects: 18

Group type: COMPARATOR
Intervention: HFA-fluticasone propionate 500 microg BD/salmeterol 100 microg BD matched placebo
Number of subjects: 18
Study: 15519629

Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IMCI facilities
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IMCI area
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-IMCI area
Number of subjects: 20
Study: 11502143

Group type: EXPERIMENTAL
Intervention: Partnership caseload midwifery care
Number of subjects: 611
Study: 9780093

Group type: EXPERIMENTAL
Intervention: Lowered intraocular pressure by 30% from baseline
Number of subjects: 140

Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 140
Study: 7825247

Group type: EXPERIMENTAL
Intervention: Multiple cytotoxic drug regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study: 29420992

Group type: EXPERIMENTAL
Intervention: High acceptability meal (HA) - vanilla custard without acesulfame-K
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low acceptability meal (LA) - vanilla custard with acesulfame-K
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both meals (HA and LA)
Number of subjects: 11
Study: 26319101

Group type: EXPERIMENTAL
Intervention: Low-velocity variable amplitude spinal manipulation (LVVA-SM)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Sham control intervention
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High-velocity low amplitude spinal manipulation (HVLA-SM)
Number of subjects: 221
Study: 24462242

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control period
Number of subjects: 0
Study: 22585294

Group type: EXPERIMENTAL
Intervention: Bladder neck mucosal eversion (BNM‐eversion) during radical retropubic prostatectomy (RRP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: No bladder neck mucosal eversion (control group) during radical retropubic prostatectomy (RRP)
Number of subjects: 211
Study: 21199608

Group type: EXPERIMENTAL
Intervention: Bilateral arm training (BAT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Distributed constraint-induced therapy (dCIT)
Number of subjects: 6
Study: 18565091

Group type: EXPERIMENTAL
Intervention: Single brief flashes of light
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple brief flashes of light
Number of subjects: 12
Study: 15784155

Group type: EXPERIMENTAL
Intervention: Risk-based prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine prevention
Number of subjects: 0
Study: 12852472

Group type: EXPERIMENTAL
Intervention: Postnatal x rays (2 or more x rays)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Polymorphism in APE gene (ex 5)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: HMLH1 (ex 8)
Number of subjects: 701
Study: 10561201

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Mitoxantrone added to prednisone after 6 weeks
Number of subjects: 161
Study: 8902431

Group type: EXPERIMENTAL
Intervention: Levofloxacin 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg (racemic mixture)
Number of subjects: 6
Study: 1861872

Group type: EXPERIMENTAL
Intervention: Desipramine (mean dose, 201 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 20
Study: 6961952

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 31878821

Group type: EXPERIMENTAL
Intervention: Children with ADHD
Number of subjects: 116308

Group type: COMPARATOR
Intervention: Children without ADHD
Number of subjects: 116308
Study: 31100237

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No ADT
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) in WW group
Number of subjects: 400
Study: 27044532

Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Number of subjects: 1028

Group type: COMPARATOR
Intervention: HeartMate II LVAS
Number of subjects: 1028
Study: 25198030

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a 5 grass pollen mixture
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 22324968

Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 30

Group type: COMPARATOR
Intervention: LMA Supreme™
Number of subjects: 30